 |
|
CLINICIAN'S CORNER
Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease
Huyen Tran, MBBS, FRACP, FRCPA;
Sonia S. Anand, MD, PhD, FRCPC
JAMA. 2004;292:1867-1874.
Context Atherothrombosis is a pathophysiologic process that results in clinical ischemic events affecting the cerebral, coronary, and peripheral arterial circulation. Antiplatelet agents, used alone or in combination, are effective in preventing recurrent vascular events among individuals with established vascular disease.
Objective To summarize the current state of evidence regarding oral antiplatelet treatment in patients with cerebrovascular disease, coronary artery disease (CAD), and peripheral arterial disease.
Evidence Acquisition Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004. We manually searched journals and abstract booklets; scrutinized reference lists of trials and review articles; and reviewed meta-analyses, scientific statements, and guidelines from official societies.
Evidence Synthesis Appropriate oral first-line antiplatelet therapy is aspirin for individuals with ST-segment elevation myocardial infarction; aspirin or clopidogrel for those with TIA or stroke, chronic stable angina, or peripheral arterial disease; and aspirin combined with clopidogrel for those with non–ST-segment elevation acute coronary syndrome. Aspirin combined with dipyridamole is a possible alternative for patients who experience a first episode of TIA or stroke in the absence of clinically apparent CAD. Although ticlopidine has been shown to be of benefit in various vascular conditions, its adverse-effect profile has limited its use.
Conclusions Aspirin, ticlopidine, clopidogrel, aspirin combined with clopidogrel, and aspirin combined with dipyridamole are effective in preventing recurrent vascular events among various subgroups of patients with vascular disease. Current clinical trial evidence favors the use of aspirin or clopidogrel as first-line agents for the majority of patients with vascular disease. Clinical trials evaluating combination antiplatelet therapies will direct future practice.
Author Affiliations: Thromboembolism Unit (Dr Tran) and Division of Cardiology (Dr Anand), Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario.
Corresponding Author: Sonia S. Anand, MD, PhD, FRCP, Department of Medicine, McMaster University Medical Center, 1200 Main St W, Room 3W28a, Hamilton, Ontario, Canada, L8N 3Z5 (anands{at}mcmaster.ca).
RELATED LETTERS
Oral Antiplatelet Therapy
Javier Borja
JAMA. 2005;293(7):793.
EXTRACT
| FULL TEXT
Oral Antiplatelet Therapy
Richard A. Bernstein and Gregory W. Albers
JAMA. 2005;293(7):793-794.
EXTRACT
| FULL TEXT
Oral Antiplatelet Therapy—Reply
Huyen Tran and Sonia S. Anand
JAMA. 2005;293(7):794-795.
EXTRACT
| FULL TEXT
Resolution of Chronic Pain and Fingertip Ulceration Due to Hand-Arm Vibration Syndrome Following Combination Pharmacotherapy
Catherine Buell, Edward Tobinick, and Karen Lamp
Arch Dermatol. 2007;143(10):1343-1344.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Antiplatelet Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes
Steven P. Schulman
JAMA. 2004;292(15):1875-1882.
ABSTRACT
| FULL TEXT
Stroke Prevention: Optimizing the Response to a Common Threat
James F. Toole, David C. Sane, and Kerstin Bettermann
JAMA. 2004;292(15):1885-1887.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke.
Dai et al.
J Am Coll Cardiol 2008;51:2173-2180.
ABSTRACT
| FULL TEXT
New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Weitz et al.
Chest 2008;133:234S-256S.
ABSTRACT
| FULL TEXT
Oral anticoagulants and non-cardioembolic stroke prevention
Schachter et al.
Vasc Med 2008;13:55-62.
ABSTRACT
Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial
Li et al.
Circulation 2008;117:553-559.
ABSTRACT
| FULL TEXT
Point-of-Care Platelet Function Testing
Harle
SEMIN CARDIOTHORAC VASC ANESTH 2007;11:247-251.
ABSTRACT
Long term medical treatment of stable coronary disease
Shavelle
Heart 2007;93:1473-1477.
FULL TEXT
Resolution of Chronic Pain and Fingertip Ulceration Due to Hand-Arm Vibration Syndrome Following Combination Pharmacotherapy
Buell et al.
Arch Dermatol 2007;143:1343-1344.
FULL TEXT
A cross sectional survey of secondary prevention measures in patients with peripheral arterial disease in primary care
Dunkley et al.
Postgrad. Med. J. 2007;83:602-605.
ABSTRACT
| FULL TEXT
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Scappaticci et al.
JNCI J Natl Cancer Inst 2007;99:1232-1239.
ABSTRACT
| FULL TEXT
Clinical Outcomes of Palliative Surgery Including a Systemic-to-Pulmonary Artery Shunt in Infants With Cyanotic Congenital Heart Disease: Does Aspirin Make a Difference?
Li et al.
Circulation 2007;116:293-297.
ABSTRACT
| FULL TEXT
A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease
Biondi-Zoccai et al.
Eur Heart J 2006;27:2667-2674.
ABSTRACT
| FULL TEXT
Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study
Hallas et al.
BMJ 2006;333:726.
ABSTRACT
| FULL TEXT
Secondary Stroke Prevention and Antiplatelet Therapy
Horton
J Am Coll Cardiol 2006;47:2568-2568.
FULL TEXT
Update in Hospital Medicine
Wiese and Holman
ANN INTERN MED 2006;144:195-200.
FULL TEXT
Antiplatelet Agents in Secondary Prevention of Stroke: A Perspective
Norris
Stroke 2005;36:2034-2036.
ABSTRACT
| FULL TEXT
Antiplatelet therapy and prevention of ischaemic events: CAPRIE
Donnelly
British Journal of Diabetes & Vascular Disease 2005;5:203-206.
Sensitivity and Specificity of the Ankle-Brachial Index to Predict Future Cardiovascular Outcomes: A Systematic Review
Doobay and Anand
Arterioscler. Thromb. Vasc. Bio. 2005;25:1463-1469.
ABSTRACT
| FULL TEXT
Arterial Elasticity as Part of a Comprehensive Assessment of Cardiovascular Risk and Drug Treatment
Cohn et al.
Hypertension 2005;46:217-220.
ABSTRACT
| FULL TEXT
Oral Antiplatelet Therapy
Borja
JAMA 2005;293:793-793.
FULL TEXT
Oral Antiplatelet Therapy
Bernstein and Albers
JAMA 2005;293:793-794.
FULL TEXT
Electrocardiographic Findings in Non-ST-Segment Elevation Myocardial Infarction
Schlegel
JAMA 2005;293:423-423.
FULL TEXT
Optimal oral antiplatelet therapy for vascular disease
BMJ 2005;330:.
FULL TEXT
Stroke Prevention: Optimizing the Response to a Common Threat
Toole et al.
JAMA 2004;292:1885-1887.
FULL TEXT
|
